1. Home
  2. BEAM vs FORTY Comparison

BEAM vs FORTY Comparison

Compare BEAM & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$29.63

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

FORTY

Formula Systems (1985) Ltd.

N/A

Current Price

$129.00

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
FORTY
Founded
2017
1985
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.1B
IPO Year
2019
1998

Fundamental Metrics

Financial Performance
Metric
BEAM
FORTY
Price
$29.63
$129.00
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$50.75
N/A
AVG Volume (30 Days)
1.5M
396.0
Earning Date
05-06-2026
05-21-2026
Dividend Yield
N/A
1.32%
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$33.77
N/A
P/E Ratio
N/A
$36.65
Revenue Growth
33.33
N/A
52 Week Low
$19.36
$102.01
52 Week High
$38.26
$190.56

Technical Indicators

Market Signals
Indicator
BEAM
FORTY
Relative Strength Index (RSI) 51.16 67.29
Support Level $28.40 $103.12
Resistance Level $31.98 $134.92
Average True Range (ATR) 1.49 0.34
MACD 0.14 2.86
Stochastic Oscillator 54.56 100.00

Price Performance

Historical Comparison
BEAM
FORTY

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

Share on Social Networks: